文 献9）Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, et al. Adrenal insufficiency related to anti-programmed death-1 therapy. Anticancer Res 2017; 37: 4229-32.10）Grünwald V, Voss MH, Rini BI, Powles T, Albiges L, Giles RH, et al. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. Br J Cancer 2020; 123: 898-904.11）Fukudo M, Tamaki G, Azumi M, Kakizaki H, Matsumoto S, Tasaki Y. Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma. Invest New Drugs 2021; 39: 595-604.12）Fukudo M, Ishikawa R, Mishima K, Ono T, Matsumoto S, Tasaki Y. Real-world nivolumab wastage and leftover drug stability assessment to facilitate drug vial optimization for cost savings. JCO Oncol Pract 2020; 16: e1134-42.13）Westerdijk K, Krens SD, van der Graaf WTA, Mulder SF, van Herpen CML, Smilde T, et al. The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. Br J Clin Pharmacol 2021; 87: 326-35.14）Fukudo M, Tamaki G, Azumi M, Shibata H, Tandai S. Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib. Br J Clin Pharmacol 2021; 87: 2132-9.15）Fukudo M, Mishima K, Kimura N, Shinden Y, Sasaki T, Okumura S, et al. Long-term follow-up of pharmacokinetics (PK) and immunogenicity of the anti–PD-1 antibodies nivolumab (Nivo) and pembrolizumab (Pembro) in real-world practice. J Clin Oncol 2019; 37(15): suppl.3120.1501）Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 2019; 58: 835-57.2）Zhao X, Suryawanshi S, Hruska M, Feng Y, Wang X, Shen J, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol 2017; 28: 2002-8.3）Basak EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, Bins S, Oomen-de Hoop E, et al. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer. Eur J Cancer 2019; 109: 12-20.4）Enrico D, Paci A, Chaput N, Karamouza E, Besse B. Antidrug antibodies against immune checkpoint blockers: Impairment of drug efficacy or indication of immune activation? Clin Cancer Res 2020; 26: 787-92.5）Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH. Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2018; 7: e1424674.6）Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, et al. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 2019; 7: 192.7）Fukudo M, Sasaki T, Ohsaki Y. PD-1 blockers: Staying long in the body and delayed toxicity risks. J Thorac Oncol 2020; 15: e42-4.8）Otsubo K, Nakatomi K, Furukawa R, Ashida K, Yoneshima Y, Nakanishi Y, et al. Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. Ann Oncol 2017; 28: 3106-7.
元のページ ../index.html#164